Galecto, Inc. announced its financial results for Q1 2025, highlighting continued progress on its dual ENL-YEATS and FLT3 inhibitor, GB3226, aimed at treating acute myeloid leukemia (AML).

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for ...

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inh Galecto Reports Full-Year 2024 ...

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...